Geodon for the Treatment of Refractory Social Anxiety Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nefazodone in the Treatment of Social Phobia

NCT00231348

Social Anxiety Disorder (SAD)

COMPLETED PHASE4

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

NCT00282828

Social Phobia

COMPLETED PHASE4

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

NCT02432703

Phobic Disorders

COMPLETED PHASE2

Quetiapine in Social Anxiety Disorder

NCT00215254

Social Anxiety Disorder

COMPLETED PHASE2/PHASE3

Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder

NCT00208741

Social Anxiety Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a two-phase study consisting of 8 weeks of open label treatment with sertraline (50-200 mg/day) in patients with SAD and in those who fail to demonstrate symptom remission on sertraline alone, 8 weeks of randomized, double-blind, placebo-controlled augmentation with ziprasidone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label Treatment

8 weeks of open label treatment with sertraline

Group Type OTHER

Sertraline

Intervention Type DRUG

Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Randomization Ziprasidone

8 weeks of treatment with sertraline augmented with ziprasidone

Group Type OTHER

Ziprasidone

Intervention Type DRUG

Sertraline augmentation with ziprasidone

Sertraline

Intervention Type DRUG

Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Randomization Placebo

8 weeks of treatment with sertraline augmented by placebo

Group Type OTHER

Sertraline

Intervention Type DRUG

Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ziprasidone

Sertraline augmentation with ziprasidone

Intervention Type DRUG

Sertraline

Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Geodon Zoloft

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults 18-65 years of age
* primary diagnosis of SAD, using Diagnostic Standard Manual(DSM-IV) criteria
* minimum Clinical Global Impression of Severity (CGI-S) score of 4 at baseline
* minimum Brief Social Phobia Scale(BSPS) score of 20 at baseline
* written informed consent
* negative serum pregnancy test for women of childbearing potential
* normal EKG

Exclusion Criteria

* current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition
* any current primary anxiety disorder other than SAD
* current primary depression
* history of substance abuse or dependence within the last 3 months
* suicide risk or serious suicide attempt within the last year
* clinically significant medical condition or laboratory or EKG abnormality
* women of childbearing potential who are unwilling to practice an acceptable method of contraception
* patients needing concurrent use of psychotropic medications
* history of hypersensitivity to sertraline or ziprasidone
* recent (less than 2 months) initiation of psychotherapy for SAD
* history of failure to respond to augmentation with an adequate trial of an atypical antipsychotic
* patients who are currently taking any of the following medications: Erythromycin, Biaxin, Avelox, Zithromax, Amantadine, Levaquin, Tamoxifen, Tegretol, Nizoral, and Levitra

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No